Kick Sarcoma Events

Calendar
Title and navigation
<<<Dec 2017>>>
Dec 2017
MonTueWedThuFriSatSun
27282930123
45678910
11121314151617
18192021222324
25262728293031
1234567
About Sarcoma  > Sarcoma FAQ

About Sarcoma

WHAT ARE THE RISK FACTORS?

Scientists do not fully understand why some people develop sarcomas while the vast majority do not. However, by identifying common characteristics in groups with unusually high occurrence rates, researchers have been able to single out some factors that may play a role in causing sarcomas.

Osteosarcoms, being the most frequent primary cancer of bone, has its highest incidence in adolescents, where it accounts for 10% of all solid cancers. Risk factors associated with the occurrence of osteosarcomas include, previous radiation therapy, Paget's disease of the bone and inherited germ line abnormalities such as the Li-Fraumeni syndrome, Werner syndrome, Rothmund-Thomson syndrome, Bloom syndrome and hereditary retinoblastoma.

Ewings sarcoma (ES) is the second most common primary malignant bone cancer, which occurs most frequently in children and adolescents, with a median age at diagnosis being 15 years.

Chondrosarcomas being the most frequently occurring bone sarcomas of adulthood can occur in multiple lesions in patients with osteochondromas and enchondromatosis.

REFERENCES:

P.C.W. HOGENDORN (on the behalf of the ESMO/ EUROBONET working group). Bone sarcomas:ESMO; Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology 21 (supplement 5); v 198-v203, 2010

P.G.Casali and J.Y. Blay (On the behalf of the ESMO/ CONTICANET/ EUROBONET consensus Panel of Experts; Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology 21 (supplement 5); v 198-v203, 2010

NOTE: The clinical Practice guidelines have been developed following a consensus based on a consensus event organized by the European Society for Medical Oncology (ESMO) in Lugano in 2009. This involved experts from the European sarcoma research groups, sarcoma networks of excellence and ESMO Faculty. CONTICANET (Connective Tissue Cancers NETwork) and EURONET (EuRopean Bone NETwork) also financially supported the consensus process.

LINKS:

Australasian Sarcoma Study Group website: www.australiansarcomagroup.org
www.team-sarcoma.net